ATNM - Actinium Pharmaceuticals, Inc.

-

$undefined

N/A

(N/A)

Actinium Pharmaceuticals, Inc. NYSE American:ATNM Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Location: 100 Park Avenue, New York, NY, 10017, United States | Website: https://www.actiniumpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-15.85M

Cash

65.33M

Avg Qtr Burn

-8.318M

Short % of Float

5.89%

Insider Ownership

1.79%

Institutional Own.

30.02%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Iomab-B (CD45) (apamistamab-I-131) Details
Hematopoietic cell transplantation , Acute myeloid leukemia

Phase 2/3

Initiation

Iomab-ACT (CAR-T – CD45) Details
Lymphoma, Diffuse large B cell lymphoma

Phase 1/2

Data readout

Actimab-A + venetoclax Details
Relapsed/refractory acute myeloid leukemia

Phase 1/2

Update

Phase 1

Data readout

Actimab-A + CLAG-M Details
Relapsed/refractory acute myeloid leukemia

Phase 1

Update

Iomab-ACT (CAR-T – CD45) Details
Sickle cell disease, Blood disorder

Phase 1

Initiation

Iomab-ACT (GeneTx – CD45) Details
Lymphoma, Acute radiation syndrome

Failed

Discontinued

Actimab-A + venetoclax Details
Myelodysplastic syndrome

Failed

Discontinued